Adriamycin (Doxorubicin) for Lymphoma

Overview

Adriamycin, also known by its drug name doxorubicin, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. Adriamycin is often combined with other drugs in specific chemotherapy regimens. Adriamycin is an anticancer drug used in chemotherapy. Adriamycin is a member of a drug class called anthracycline antibiotics. Adriamycin is also a topoisomerase inhibitor. Adriamycin is believed to work by damaging DNA and blocking cell division in several ways.

How do I take it?

Adriamycin is usually administered as an intravenous infusion during chemotherapy treatment.

Side effects

The FDA-approved label for Adriamycin lists common side effects including hair loss, nausea, and vomiting. Rare but serious side effects listed for Adriamycin include radiation-induced toxicity and fetal harm.

For more details about this treatment, visit:

Adriamycin PFS

Chemotherapy for Hodgkin Lymphoma — American Cancer Society

Chemotherapy for Non-Hodgkin Lymphoma — American Cancer Society

Drug Therapy for Multiple Myeloma — American Cancer Society